Martin, William P.William P.Martinle Roux, Carel W.Carel W.le Roux2021-11-292021-11-292019 Ameri2019-06-01Surgery for Obesity and Related Diseases1550-7289http://hdl.handle.net/10197/12674Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and significantly elevates cardiovascular disease risk [1]. Persons with DKD accounted for 45.4% and 38.2% of incident and prevalent cases of end-stage renal disease in the United States in 2015, respectively [2]. Current management of DKD focuses on control of hyperglycemia and hypertension along with renin-angiotensin-aldosterone system blockade to minimize proteinuria. The most notable recent advances in DKD care include sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 agonists, which reduce glycosylated hemoglobin (A1C), blood pressure, weight, cardiovascular mortality, and nephropathy progression [ 3]. Despite this, existing therapies for DKD slow the rate of renal functional decline rather than reversing it.Print-ElectronicenThis is the author’s version of a work that was accepted for publication in Surgery for Obesity and Related Diseases. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Surgery for Obesity and Related Diseases (15, 6, (2019)) https://doi.org/10.1016/j.soard.2019.04.001KidneyHumansMorbid obesityWeight lossBariatric SurgeryJournal Article1561020102310.1016/j.soard.2019.04.0012020-10-20203930/B/16/Zhttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/